FDA Recalls Flunisolide Nasal Solution Due to Out-of-Specification Impurities
Ingenus Pharmaceuticals is recalling Flunisolide Nasal Solution nationwide because the product contains impurities that exceed acceptable limits. The recall affects two lots distributed across the United States.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall for a quality-control issue (out-of-specification impurities) with no reported hospitalizations, illnesses, or injuries. The hazard is precautionary in nature, consistent with a moderate-severity contamination recall.
Plain-English summary
Ingenus Pharmaceuticals LLC is recalling Flunisolide Nasal Solution, USP 0.025% (25 mL bottles) nationwide. The recall is due to the product being out of specification for related substances, meaning it contains impurities that exceed acceptable limits.
The affected lots are #22E040 (Exp. 07/2023) and #22F038 (Exp. 08/2023). A total of 6,176 bottles were distributed nationwide within the United States. The product is identified by NDC 50742-317-25.
This is a Class II recall issued by the FDA.
The recalled product
- Product
- FLUNISOLIDE (FLUNISOLIDE)
- Brand
- FLUNISOLIDE
- Manufacturer
- Ingenus Pharmaceuticals Llc
- Category
- Drug — Nasal Solution
- Hazard
- impurities
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 22E040 Exp. 07/2023
- 22F038 Exp. 08/2023
UPCs (1)
- 350742317257
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27